DiaMedica Therapeutics Inc (DMAC)
2.58
+0.05
(+1.98%)
USD |
NASDAQ |
May 01, 16:00
DiaMedica Therapeutics Enterprise Value: 45.04M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 45.04M |
| April 30, 2024 | 43.14M |
| April 29, 2024 | 45.42M |
| April 26, 2024 | 44.66M |
| April 25, 2024 | 43.14M |
| April 24, 2024 | 40.10M |
| April 23, 2024 | 38.96M |
| April 22, 2024 | 42.38M |
| April 19, 2024 | 37.82M |
| April 18, 2024 | 41.62M |
| April 17, 2024 | 45.80M |
| April 16, 2024 | 37.07M |
| April 15, 2024 | 37.82M |
| April 12, 2024 | 39.34M |
| April 11, 2024 | 43.52M |
| April 10, 2024 | 47.69M |
| April 09, 2024 | 49.97M |
| April 08, 2024 | 52.63M |
| April 05, 2024 | 60.22M |
| April 04, 2024 | 59.08M |
| April 03, 2024 | 53.39M |
| April 02, 2024 | 50.73M |
| April 01, 2024 | 50.73M |
| March 28, 2024 | 52.25M |
| March 27, 2024 | 47.69M |
| Date | Value |
|---|---|
| March 26, 2024 | 50.35M |
| March 25, 2024 | 48.83M |
| March 22, 2024 | 51.49M |
| March 21, 2024 | 49.21M |
| March 20, 2024 | 52.25M |
| March 19, 2024 | 54.15M |
| March 18, 2024 | 55.29M |
| March 15, 2024 | 62.12M |
| March 14, 2024 | 57.94M |
| March 13, 2024 | 57.18M |
| March 12, 2024 | 56.80M |
| March 11, 2024 | 57.56M |
| March 08, 2024 | 63.26M |
| March 07, 2024 | 63.64M |
| March 06, 2024 | 61.74M |
| March 05, 2024 | 64.77M |
| March 04, 2024 | 68.76M |
| March 01, 2024 | 63.64M |
| February 29, 2024 | 60.98M |
| February 28, 2024 | 62.12M |
| February 27, 2024 | 59.84M |
| February 26, 2024 | 54.91M |
| February 23, 2024 | 54.53M |
| February 22, 2024 | 56.04M |
| February 21, 2024 | 57.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-6.711M
Minimum
Sep 26 2022
168.02M
Maximum
Feb 19 2021
50.28M
Average
45.50M
Median
Dec 21 2021
Enterprise Value Benchmarks
| NextCure Inc | -69.51M |
| NovaBay Pharmaceuticals Inc | 2.654M |
| Palatin Technologies Inc | 20.69M |
| iBio Inc | 16.31M |
| Theriva Biologics Inc | -13.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.161M |
| Total Expenses (Quarterly) | 5.848M |
| EPS Diluted (Quarterly) | -0.14 |
| Earnings Yield | -24.03% |